Path From Clinical Research to Implementation

Eveline J.A. Wiegers,Kars C.J. Compagne,Paula M. Janssen,Esmee Venema,Jaap W. Deckers,Wouter J. Schonewille,Jan Albert Vos,Geert J. Lycklama à Nijeholt,Bob Roozenbeek,Jasper M. Martens,Jeannette Hofmeijer,Robert-Jan van Oostenbrugge,Wim H. van Zwam,Charles B.L.M. Majoie,Aad van der Lugt, H.F. Lingsma,Yvo B.W.E.M. Roos,Diederik W.J. Dippel,Jelis Boiten,Josje Brouwer,Sanne J. den Hartog,Wouter H. Hinsenveld,Manon Kappelhof,Robert-Jan B. Goldhoorn,Maxim J.H.L. Mulder,Ivo G.H. Jansen,Adriaan C.G.M. van Es,Bart J. Emmer,Jonathan M. Coutinho,Marieke J.H. Wermer,Marianne A.A. van Walderveen,Julie Staals,Jelis Boiten,Sebastiaan F. de Bruijn,Lukas C. van Dijk,H. Bart van der Worp,Rob H. Lo,Ewoud J. van Dijk,Hieronymus D. Boogaarts,J. de Vries,Paul L.M. de Kort,Julia van Tuijl, Jo Jo P. Peluso,Puck Fransen,Jan S.P. van den Berg,Boudewijn A.A.M. van Hasselt,Leo A.M. Aerden,René J. Dallinga,Maarten Uyttenboogaart,Omid Eschgi,Reinoud P.H. Bokkers,Tobien H.C.M.L. Schreuder,Roel J.J. Heijboer,Koos Keizer,Lonneke S.F. Yo,Heleen M. den Hertog,Emiel J.C. Sturm,Paul Brouwers,Marianne A.A. van Walderveen,Marieke E.S. Sprengers,Sjoerd F.M. Jenniskens,René van den Berg,Albert J. Yoo,Ludo F.M. Beenen,Alida A. Postma,Stefan D. Roosendaal, Bas F.W. van der Kallen,Ido R. van den Wijngaard, Adriaan C.G.M. van Es,Bart J. Emmer,Lonneke S.F. Yo,Joost Bot,Pieter-Jan van Doormaal,Anton Meijer, Elyas Ghariq,Reinoud P.H. Bokkers, Marc P. van Proosdij, G. Menno Krietemeijer,Jo P. Peluso,Hieronymus D. Boogaarts,Rob Lo,Dick Gerrits, Wouter Dinkelaar,Auke P.A. Appelman,Bas Hammer,Sjoert Pegge,Anouk van der Hoorn,Saman Vinke,Jelis Boiten,H. Bart van der Worp,Rob H. Lo,H. Zwenneke Flach, Naziha el Ghannouti,Martin Sterrenberg,Corina Puppels, Wilma Pellikaan,Rita Sprengers, Marjan Elfrink, Michelle Simons,Marjolein Vossers,Joke de Meris,Tamara Vermeulen,Annet Geerlings,Gina van Vemde,Tiny Simons, Cathelijn van Rijswijk,Gert Messchendorp,Nynke Nicolaij, Hester Bongenaar, Karin Bodde,Sandra Kleijn, Jasmijn Lodico,Hanneke Droste,Maureen Wollaert,Sabrina Verheesen, D. Jeurrissen,Erna Bos,Yvonne Drabbe,Michelle Sandiman, Marjan Elfrink,Nicoline Aaldering,Berber Zweedijk, Mostafa Khalilzada,Jocova Vervoort,Hanneke Droste,Nynke Nicolaij, Michelle Simons,Eva Ponjee,Sharon Romviel, Karin Kanselaar,Erna Bos,Denn Barning,Vicky Chalos,Ralph R. Geuskens, Tim van Straaten,Saliha Ergezen,Roger R.M. Harmsma,Daan Muijres, Anouk de Jong,Olvert A. Berkhemer,Anna M.M. Boers, J. Huguet, P.F.C. Groot, Marieke A. Mens,Katinka R. van Kranendonk,Kilian M. Treurniet,Ivo G.H. Jansen,Manon L. Tolhuisen,Heitor Alves,Annick J. Weterings, Eleonora L.F. Kirkels,Eva J.H.F. Voogd,Lieve M. Schupp,Sabine Collette,Adrien E.D. Groot,Natalie E. LeCouffe,Praneeta R. Konduri,Haryadi Prasetya,Nerea Arrarte-Terreros,Lucas A. Ramos

Stroke(2020)

引用 1|浏览12
暂无评分
摘要
Before 2015, endovascular treatment (EVT) for acute ischemic stroke was considered a promising treatment option. Based on limited evidence, it was performed in several dedicated stroke centers worldwide on selected patients. Since 2015, EVT for patients with intracranial large vessel occlusion has quickly been implemented as standard treatment in many countries worldwide, supported by the revised international guidelines based on solid evidence from multiple clinical trials. We describe the development in use of EVT in the Netherlands before, during, and after the pivotal EVT trials. We used data from all patients who were treated with EVT in the Netherlands from January 2002 until December 2018. We undertook a time-series analysis to examine trends in the use of EVT using Poisson regression analysis. Incidence rate ratios per year with 95% CIs were obtained to demonstrate the impact and implementation after the publication of the EVT trial results. We made regional observation plots, adjusted for stroke incidence, to assess the availability and use of the treatment in the country. In the buildup to the MR CLEAN (Multicenter Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands), a slow increase of EVT patients was observed, with 0.2% of all ischemic stroke patients receiving EVT. Before the trial results were formally announced, a statistically significant increase in EVT-treated patients per year was observed (incidence rate ratio, 1.72 [95% CI, 1.46–2.04]), and after the trial publication, an immediate steep increase was seen, followed by a more gradual increase (incidence rate ratio, 2.14 [95% CI, 1.77–2.59]). In 2018, the percentage of ischemic stroke patients receiving EVT increased to 5.8%. A well-developed infrastructure, a pragmatic approach toward the use of EVT in clinical practice, in combination with a strict adherence by the regulatory authorities to national evidence-based guidelines has led to successful implementation of EVT in the Netherlands. Ongoing efforts are directed at further increasing the proportion of stroke patients with EVT in all regions of the country.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要